Cargando…

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No

Detalles Bibliográficos
Autor principal:	Rotstein, Dalia L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Controversies in Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315179/ https://www.ncbi.nlm.nih.gov/pubmed/35437080 http://dx.doi.org/10.1177/13524585221091060

Ejemplares similares

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
por: Cree, Bruce AC
Publicado: (2022)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes
por: Scalfari, Antonio
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
por: Mühlau, Mark
Publicado: (2022)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

Studying the blood–brain barrier will provide new insights into neurodegeneration – Yes
por: Kamphuis, Wouter W, et al.
Publicado: (2018)

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach – NO
por: Hulst, Hanneke E, et al.
Publicado: (2017)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Commentary
por: Hohlfeld, R
Publicado: (2021)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
por: Gastaldi, Matteo, et al.
Publicado: (2023)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies
por: Hedström, A K, et al.
Publicado: (2016)

T cell composition and polygenic multiple sclerosis risk: A population‐based study in children
por: de Mol, Casper L., et al.
Publicado: (2021)

Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population
por: de Mol, Casper L., et al.
Publicado: (2022)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
por: Biström, M., et al.
Publicado: (2020)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study
por: Åkerstedt, Torbjörn, et al.
Publicado: (2023)

HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study
por: Gold, Julian, et al.
Publicado: (2015)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v57a516set04cl23abts28flve